Be The Match BioTherapies

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program (NMDP)/Be The Match, we have unparalleled experience managing cellular therapies. Our cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a technology platform, MatchSource®. Our experience in cell sourcing and collection allows us to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through our research program CIBMTR. And, we have the infrastructure in place to collect, store and analyze patient samples post-cell or gene therapy treatment at the time points required by regulatory authorities.

Strategies for successful commercial-readiness in gene therapy

Insights from Orchard’s HSC gene therapy supply chain development

Another record year for cell and gene therapies?

Pipeline continues to expand along with regulatory decisions

HLA’s future impact on allogeneic cell therapy development

From cell bank creation to maximizing population coverage

Supporting transformational treatments for rare disorders

A Rare Disease Day retrospective

Advancements in cell and gene therapy

2020 year-in-review

Transforming patient care through cell and gene therapy

Cell therapy advances highlighted during The ONE Forum 2020

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

A roundup of COVID-19 treatments in development

How COVID-19 is accelerating cell therapy innovation

6 Considerations When Evaluating Cell Sourcing Vendors

Including questions to ask potential cell sourcing partners